Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients

This study is comparing two approaches to preventing graft-versus-host disease (GVHD — a serious complication where donor immune cells attack the recipient's body) in patients with acute leukemia receiving a stem cell transplant from a matched family donor. **You may be eligible if...** - You have acute leukemia (AML or ALL) that is in complete remission - You have a fully matched related donor (8 out of 8 markers matched) willing to donate stem cells - Your heart, lungs, kidneys, and liver function are within required ranges - You are planned to receive a high-intensity (myeloablative) conditioning regimen before transplant **You may NOT be eligible if...** - Your leukemia is still active at the time of transplant - You have uncontrolled infections (bacterial, viral, or fungal) - Your overall physical condition is significantly impaired (Karnofsky/Lansky score below 70%) - You have previously received a stem cell transplant Talk to your doctor to see if this trial is right for you.